Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phenylephrine
Drug ID BADD_D01762
Description Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.[A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413]
Indications and Usage Phenylephrine injections are indicated to treat hypotension caused by shock or anesthesia,[L9416, L9410] an ophthalmic formulation is indicated to dilate pupils[L9413] and induce vasoconstriction, an intranasal formulation is used to treat congestion, and a topical formulation is used to treat hemorrhoids.[A187370] Off-label uses include situations that require local blood flow restriction such as the treatment of priapism.[A187370]
Marketing Status approved
ATC Code C01CA06; R01AA04; R01AB01; R01BA03; S01FB01; S01GA05
DrugBank ID DB00388
KEGG ID D08365
MeSH ID D010656
PubChem ID 6041
TTD Drug ID D0O6IU
NDC Product Code 57218-710
UNII 1WS297W6MV
Synonyms Phenylephrine | (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol | Metasympatol | Mezaton | Phenylephrine Hydrochloride | Phenylephrine Tannate | Tannate, Phenylephrine | Metaoxedrin | Neo-Synephrine | Neo Synephrine | Neosynephrine
Chemical Information
Molecular Formula C9H13NO2
CAS Registry Number 59-42-7
SMILES CNCC(C1=CC(=CC=C1)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rales22.12.01.011--Not Available
Respiratory distress22.02.01.012--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin necrosis23.03.03.011--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.002066%Not Available
Syncope24.06.02.012; 02.11.04.015; 17.02.04.008--
Tachycardia02.03.02.0070.001377%Not Available
Tension19.06.02.005--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Ventricular arrhythmia02.03.04.006--
Ventricular extrasystoles02.03.04.007--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Vitreous floaters06.09.01.005--
Vomiting07.01.07.003--
Underweight14.03.02.017--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Angiopathy24.03.02.007--Not Available
Cardiac disorder02.11.01.003--Not Available
Ischaemia24.04.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Urinary tract obstruction20.08.01.004--
Acute kidney injury20.01.03.016--
Sensitisation10.02.01.012; 08.01.05.009--Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.001377%
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages